ReviewJournal of cutaneous medicine and surgery
A Review of Existing and New Treatments for the Management of Hand Eczema.
Review in Journal of cutaneous medicine and surgery. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 1 synthesis or guideline pooled it, 27 citations in OpenAlex.
- Efficacy and safety of dupilumab in chronic hand eczema: a systematic review.Archives of dermatological research · 2025Pooled it
- Real-Life Workup of Chronic Hand Eczema Using a Dedicated Case Report Form: A SIDAPA Multicentre Study.Contact dermatitis · 2026Article
- Expert Recommendations for the Diagnosis and Management of Chronic Hand Eczema in the United States.American journal of clinical dermatology · 2026Review
- Exploring Two New, Validated Disease-Specific Outcome Measures to Assess Severity of Chronic Hand Eczema: Investigator Global Assessment of Chronic Hand Eczema (IGA-CHE) and Hand Eczema Symptom Diary (HESD)-A Podcast.Dermatology and therapy · 2026Article
- A Practical Approach to Chronic Hand Eczema.Dermatology and therapy · 2025Article
- Efficacy and Safety of Dupilumab vs Narrowband UVB for the Treatment of Chronic Hand Dermatitis: A Retrospective Study.Acta dermato-venereologica · 2025Article
- Chronic Hand Eczema, Real World, and Patient Centricity: A Narrative Review.Acta dermato-venereologica · 2025Review
- Chronic Hand Eczema (CHE): A Narrative Review.Dermatology and therapy · 2025Review
- Review
- Knowledge, attitudes, and practices of hand eczema patients in Guangdong, China.Frontiers in public health · 2025Article
- Italian Expert Opinion on Chronic Hand Eczema: from Guidelines to Clinical Practice.Dermatology and therapy · 2025Article
- Chronic Hand Eczema.American journal of clinical dermatology · 2024Review
- Satisfaction with Control of Mild to Moderate Atopic Dermatitis with Ruxolitinib Cream: US Physician and Patient Perspectives.Dermatology and therapy · 2024Article
- Hand Eczema in the Polish Female Population.Journal of clinical medicine · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Hand eczema is a chronic condition that affects an estimated 14.5% of the general population. It has severe quality of life ramifications in those that struggle with it, including days missed from work or school, productivity loss and impaired work functioning. For years, the standard of care included topical moisturizing creams, topical steroids and more recently systemic agents. As new therapeutic targets emerge and recent advances are being developed, it is now more possible than ever that hand eczema can be managed via the underlying mechanisms. A review of the literature was conducted to identify current treatment options for hand eczema and chronic hand eczema. The terms 'hand eczema', 'hand dermatitis' were used to search PubMed, CENTRAL and Embase. To identify new therapies still undergoing investigation, we used the terms 'hand eczema', 'hand dermatitis', 'atopic dermatitis', and 'vesicular eczema of hands and/or feet' to search Clinicaltrials.gov for all studies until December 2022. There were 56 ongoing clinical trials identified for pharmacological treatments for hand eczema on Clinicaltrials.gov from 2000 - 2022, with 16 that are new or ongoing. These included studies for dupilumab, ruxolitinib, delgocitinib (LEO124249), gusacitinib (ASN002), AFX 5931, and roflumilast (ARQ-252). Two major classes of drugs emerging for the treatment of hand eczema include IL-4/IL-13 inhibitors and JAK inhibitors. With the increase in efficacy seen with these new drugs, we are also noting improved adverse effect profiles, making them attractive options to add to a clinician's management toolbox for patients with hand eczema.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.